The Power of Radiotherapy

The Specificity of Molecular Targeting

for Better
Patient Outcomes

Because Cancer Patients
Need a New Approach

Commitment

Andarix Pharmaceuticals is developing and commercializing novel cancer therapies that are targeted to the patients most likely to respond. Tozaride, our lead product entering Phase 2 clinical trials, targets specific cancers at the molecular level, and its companion diagnostic  identifies the patients with the corresponding molecular signature who are the best candidates for therapy.

commitment

Targeted Therapies
for Personalized Medicine

Peptide targeted radiotherapy is a promising new approach to cancer therapy and has been widely validated in clinical studies as well as in routine clinical use in Europe. Treating cancer with radiotherapy can achieve results not possible with conventional therapies because cancer cells are unable to evade the lethal damage caused by targeted radiation.

News & Events

Andarix Pharmaceuticals to Present Targeted Lung Cancer Technology at Clinical Conference

Oct 17, 2022

Targeted therapy for lung cancer is based on personalized medicine approach SOMERVILLE, MA — October 12, 2022— ANDARIX Pharmaceuticals, a leader in the discovery and development of targeted peptide therapy for cancer announced today that it will present its technology for treating lung cancer patients at a clinical provider conference. The conference will focus on…

Read More

Andarix Pharmaceuticals to Present Lung Cancer Therapy Technology at Clinical Trials Conference

Oct 14, 2022

Targeted therapy for lung cancer is based on personalized medicine approach SOMERVILLE, MA —July 23, 2022— ANDARIX Pharmaceuticals, a leader in the discovery and development of targeted peptide therapy for cancer announced today that it will present its technology for treating lung cancer patients at a therapeutics conference. The conference will focus on a diversity…

Read More

Andarix Pharmaceuticals Awarded Trademark for Tozaride by the US Patent and Trademark Office

Apr 26, 2019

Targeted therapy for cancer is based on personalized medicine approach SOMERVILLE, MA — March 2, 2019— Andarix Pharmaceuticals, a leader in the discovery and development of targeted peptide therapy for cancer announced today that it has been granted the US trademark for Tozaride by the United States Patent and Trademark Office. About Tozaride Tozaride is…

Read More